Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's IPR (intellectual property rights) enforcement promises followed up by US:

This article was originally published in Clinica

Executive Summary

China's claims that progress is being made to enforce intellectual property rights (IPR) are to be assessed by the World Trade Organisation (WTO) at the behest of the US. What is known as an "Article 63" request has been made by the US Trade Representative (USTR) and requires that China detail the specific actions it has taken to enforce IPR. Article 63.3 is part of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which allows WTO members to request information on judicial decisions or administrative rulings related to IPR that affects their rights under the agreement. The move highlights the continuing US concerns that China has not provided sufficient detail about its IPR enforcement programme. The action builds on the July US-China Joint Commission on Commerce and Trade meeting in Beijing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel